Armed Forces Laser Module Manual
Many types of CNC machines and 3D printers with different control voltage standards and levels available on the market may be used to control the PLH3D head. The PLH3D-CNC Adapter converts all these signals to the standard compatible with the PLH3D head. The general status (power, armed, laser working) may be checked at a glance by watching three LEDs.
Armed Forces Laser Module Manual
A special circuitry prevents arming at any malfunction of internal electronics. The laser head is automatically disarmed in case of emergency: loss of the mains supply, PSU failure, breaking or disconnecting the laser head cable. After disarming, the system remains in a safe state, and rearming always requires pressing the button by the user.
Layout table for study information Study Type : Interventional (Clinical Trial) ActualEnrollment : 37 participants Allocation: N/A Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: The Safety and Efficacy of Trio Diode Laser Module for Hair Removal Treatment in All Skin Types Actual Study Start Date : October 7, 2020 Actual Primary Completion Date : October 7, 2021 Actual Study Completion Date : November 16, 2021 Arms and Interventions Go to Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information Arm Intervention/treatment Experimental: Hair removal treatmentTrio laser module (Alma Lasers) Device: Hair removal treatmentAxilla and bikini line hair removal treatments using the Trio Laser Module (Alma Lasers). Outcome Measures Go to Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information Primary Outcome Measures : Change in hair count [ Time Frame: 3 month after the last treatment ]Change in hair count, preformed by blinded evaluators, based on photographs taken at 3m FU visit compared to baseline Safety- Adverse events [ Time Frame: Through study completion, an average of 1 year ]Adverse events and serious AE reported at any time during the trial or follow-up Secondary Outcome Measures : Investigator's assessment of the tolerability to the treatment using a 5-point Likert scale (when "0" indicates "none" and "4" indicates "sever"). [ Time Frame: up to 24 weeks ]The investigator will assess the treatment area and score treatment related side effects using a 5-point likert scale, before and after the treatment Subject's tolerability to the treatment, using a 5-point Likert scale (when "0" indicates "none" and "4" indicates "sever"). [ Time Frame: up to 24 weeks ]Subjects will be requested to scale any sensation of stinging, tingling, itching and, burning using the 5-point Likert scale, before and after the treatment Subject treatment related pain assessment, using VAS ( when "0" indicates "no pain" and "10" " worst possible pain" [ Time Frame: up to 24 weeks ]Subjects will be requested to scale their treatment related pain Subject's satisfaction from the treatment, using a 5-point Likert scale (when "1" indicates very dissatisfied and "5" very satisfied) [ Time Frame: 3 months after the last treatment ]Subjects will be requested to scale their satisfaction from the treatment Eligibility CriteriaGo to Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies. Layout table for eligibility information Ages Eligible for Study: 18 Years to 70 Years (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: Yes Criteria Inclusion Criteria: 350c69d7ab